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observed secondary to traumatic induction of OA by anterior
cruciate ligament transection (ACLT).
Methods: Four groups of 10 female rats were subjected to ei-
ther sham or ACLT surgery in both knee joints and administered
twice a day for 28 days with an oral dose of salmon calci-
tonin (150mg/kg 5-CNAC + 2mg/kg calcitonin) or vehicle control
(150mg/kg 5-CNAC). Serum samples were collected at baseline
and 7, 14, 21 and 28 days and weights were recorded at reg-
ular intervals. Cartilage degradation was evaluated in serum by
C-terminal telopeptide of type II collagen (CTX-II ELISA). Knee
joints were collected at euthanasia and one was processed
for histology and immunohistochemistry (IHC). Sections were
scored on a modiﬁed Mankin score for proteoglycan content,
chondrocytes cloning and cartilage erosion on a scale from 0-4,
where the score 4 was most severe damage. Immunolocalization
of antibodies towards CTX-II fragments, MMP-13 expression and
proliferation (Ki67) was visualized by IHC.
Results: Treatment with salmon calcitonin signiﬁcantly reduced
serum CTX-II levels in sham+calcitonin animals on day 14 (52%,
P<0.05) and day 28 (49%, P<0.001), compared to the con-
trol group. Treatment with calcitonin also reduced CTX-II levels
in the ACLT+calcitonin groups on day 14 (50%, P<0.01) and
day 28 (41%, P<0.05), compared to the control group. ACLT
operated knees resulted in a 40% signiﬁcant (P<0.001) in-
crease in total Mankin score. Calcitonin restored Mankin score
to below sham levels, (P<0.05). The most promising effect was
observed on cartilage erosion. MMP-13 expression and CTX-II
fragments were co-localized in the articular cartilage surface in
the eroded areas. Serum CTX-I levels decreased in calcitonin
treated animals compared to sham operated animals (36%,
P<0.001).
Conclusions: Currently there are no treatments available for
OA. Calcitonin has recently been proposed as a potential treat-
ment for OA. These data are the ﬁrst to demonstrate that an oral
formulation of calcitonin protect against cartilage degradation in
an in vivo model of joint trauma and increased cartilage degra-
dation. The chondroprotective effect of salmon calcitonin may
be a combination of direct effects on chondrocytes in addition
to the well-established effect on bone resorption. Further clinical
studies are needed to validate the herein documented effects on
cartilage erosion.
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Purpose: The most frequently used model for osteoarthritis (OA)
is the canine joint instability, viz. ACLT, model. The ACLT model
can be extended with a medial meniscectomy (i.e., ACLT-Mx
model) to avoid unintentional, and with that variable, meniscal
damage. More recently the canine Groove model has been
developed in which OA is caused by surgically induced cartilage
damage combined with temporary intermittent forced loading of
the joint. Both models demonstrated comparable development
of cartilage damage but they have never been compared on
changes in gait as measure of pain/disability. Such a clinical
measure is, in addition to structural parameters of joint damage
and inﬂammation, of major importance in evaluation of treatment
strategies of OA.
Methods: Knee osteoarthritis (OA) was induced in Labrador
dogs according to the ACLT-Mx model (n=7) or Groove model
(n=7). Every four weeks standardized radiographs were taken
to analyze osteophyte formation. Every two weeks gait was
recorded using Force Plate Analysis (FPA). Joints were macro-
scopic, histological, and biochemical analyzed for features of OA,
12 weeks after induction of OA.
Results: Radiographs revealed osteophyte formation in the ex-
perimental joints at the expected locations and the overall os-
teophyte score increased signiﬁcantly (p<0.05) over time for
both models. Cartilage integrity was damaged as reﬂected by
an increased macroscopic ( 1.5 vs. 1), and histological score
( 3 vs. 2.5) and a decreased proteoglycan content (-29% vs.
-18%) for the ACLT-Mx model and Groove model, respectively
(all p<0.05). Chondrocyte activity demonstrated an increased
synthesis rate (+70% vs. +10%) and release of proteoglycans
(+200% vs. +60%) for the ACLT-Mx model and Groove model,
respectively (both p<0.05). Synovial inﬂammation revealed the
same characteristics in both models ( 3.5 vs. 1.0 and 1.2 vs. 0.8
for macroscopic and histological inﬂammation in the, ACLT-Mx vs.
Groove model, respectively). Gait analysis revealed, a decrease
in the three peak ground reaction forces of the experimental leg
after OA induction (p<0.05), ranging from -80% in the ACLT-MX
model to -40% in groove model, statistically different between
both models (p<0.05). On average the ACLT-Mx demonstrated
more pronounced changes compared to the Groove model. In-
terestingly, the change in gait (all three ground reaction forces)
correlated signiﬁcantly with the change in cartilage integrity (pro-
teoglycan content and histological grade; r=0.445, r=0.488, and
r=0.542 for peak braking, stance, and propelling force, respec-
tively; all p<0.003).
Conclusions: The ACLT-Mx model demonstrates all the charac-
teristics of OA and can be designated as a moderate to severe
model of OA with clear synovial inﬂammatory activity. The Groove
model is a less painful and signiﬁcantly milder model of OA. The
latter might be more suitable to study subtle changes as a result
of intervention than the more robust ACLT-Mx model. Moreover,
gait might be used as a surrogate measure of pain/disability.
Most important, degree of cartilage damage is reﬂected by the
extent to which the OA joint was (un)loaded.
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Purpose: Appropriate dosage of intra-articular injections of
drugs with potentially beneﬁcial structural or symptomatic ef-
fects on articular cartilage requires information on the cartilage
surface area, and potentially, on the cartilage thickness and vol-
ume. As various animal models are used to test the effect of
such drugs in preclinical models, the aim of the current study
was to provide quantitative, three-dimensional data on the tibial
cartilage surface areas, cartilage thickness and cartilage volume
in a variety of animal species and in humans.
Methods: The knees of 16 male Sprague Dawley rats (body
weight 300 g) and 6 rabbits (weight 3.5 kg) were investigated
with magnetic resonance imaging at 7 Tesla (T), and the knees
and the knees of 3 cats (weight 4.2 kg), 18 mongrel dogs (weight
25 kg), 1 pig (weight 110 kg), 1 horse (weight 535 kg) and 1
rhinoceros (weight 1200 kg) at 1.5T. The values were compared
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Abstract 79 – Knee cartilage morphology in various species and humans
Species Number Cartilage surface area Cartilage thickness Cartilage volume
Rat 16 6.2±0.9 mm2 0.14±0.12 mm 0.81±0.17 mm3
Rabbit 6 69±4.9 mm2 0.37±0.05 mm 23.5±3.9 mm3
Cat 3 85±9.1 mm2 0.67±0.05 mm 55.8±10.5 mm3
Dog 18 196±18 mm2 0.77±0.04 mm 142±15 mm3
Pig 1 1650 mm2 1.4 mm 2200 mm3
Horse 1 2390 mm2 1.4 mm 3290 mm3
Rhinoceros 1 5460 mm2 1.8 mm 9840 mm3
Human (Women) 45 1050±135 mm2 1.9±0.23 mm 1940±344 mm3
Human (Men) 72 1380±205 mm2 2.2±0.26 mm 2940±622 mm3
with those in a data base of young (18 to 35 years) healthy
humans (45 women, weight 60 ± 7 kg, and 72 men, weight 77
± 11 kg) who had been imaged at 1.5T. Sagittal spoiled gradient
echo sequences with fat suppression or water excitations were
acquired in all knees. The medial tibial cartilage was segmented
by tracing the cartilage surface (AC) and subchondral bone area
(tAB) throughout the entire medial tibia. The size of the cartilage
surface areas (AC), the mean cartilage thickness (ThC) and
the cartilage volume (VC) were computed using Chondrometrics
software (Ainring, Germany).
Results: The size of the cartilage surface areas in the rat (6.2
mm2) was approximately 200x smaller than that in humans (Table
1), whereas that in the rhinoceros was about 4.5 x larger than
than in humans. The variability of cartilage thickness between
the species, however, was substantially less than for cartilage
surface areas. All species (including the rhinoceros: ThC = 1.8
mm) had thinner cartilage than humans (1.9 mm in women and
2.2 mm in men, respectively). The rat displayed the lowest mean
cartialge thickness (0.14 mm) amongst the species investigated.
Conclusions: To our knowledge these are the ﬁrst quantitative
data on the three-dimensional morphology of tibial cartilage in
different species and humans. The data show that the inter-
species differences in cartilage surface areas are much more
prominent than those in cartilage thickness. This is likely due to
the need to keep mechanical stresses (load/area) below a critical
threshold at which the cartilage will undergo damage. These data
can be used to estimate the appropriate dose of intra-articular
medication with potentially beneﬁcial structural or symptomatic
effects on articular cartilage in animal models of OA.
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THERAPEUTIC EFFECTS OF FIBROBLAST GROWTH
FACTOR-18 IN A RAT MODEL OF ESTABLISHED
OSTEOARTHRITIS
C.H. Ladel1, J.L. Ellsworth2, A.M. Bendele3, A. Gimona4,
S. Riva1, E. Vom Baur4
1Merck Serono Research - RBM, Colleretto Giacosa, Italy;
2ZymoGenetics, Inc, Seatlle, WA; 3Bolder BioPATH, Inc., Bolder,
CO; 4Merck Serono S.A., Geneve, Switzerland
Purpose: FGF18 plays a central role in skeletal growth and
development. In contrast to its described role in the growth
plate, where it negatively regulates chondrocyte proliferation and
differentiation, FGF18 has been shown to have signiﬁcant an-
abolic effects on chondrocytes in other cartilaginous tissues. To
evaluate whether recombinant human FGF18 (rhFGF18) could
facilitate the repair of cartilage damage caused by osteoarthritis
(OA), the efﬁcacy of rhFGF18 was tested in a rat meniscal tear
model of OA.
Methods: In the rat meniscal tear model, a full-thickness cut
in the medial meniscus leads to joint instability and progressive
development of OA characterized by proteoglycan loss, cartilage
ﬁbrillation, chondrocyte death, eventual damage to the subchon-
dral bone, and formation of osteophytes.
rhFGF18, formulated in saline, was administered by intra-
articular injection beginning 21 days after meniscal tear using
three different dose regimens: once per week, twice per week
or three times per week with 0, 0.3, 1, 3 or 10 µg/joint overall
weekly dose. Evaluation was performed at 3 weeks and, further
to an initial evaluation of rhFGF18 in this model, at a 3-week
follow-up period after end of therapy to investigate sustained
cartilage effects of rhFGF18.
Results: Treatment with rhFGF18 induced a dose-dependent
increase in cartilage formation and a statistically signiﬁcant in-
crease in the thickness of the articular surface of the medial tibial
plateau. The increase in cartilage formation induced by rhFGF18
was paralleled by signiﬁcant reductions in multiple degeneration
scores. Anabolic effects were seen in most groups and were
greatest in the joints treated 3x/week but this dosing paradigm
also resulted in excessive inﬂammation and bone resorption.
Weekly dosing with 10 or 3 µg resulted in high therapeutic
efﬁcacy. Animals given 3 or 10 µg rhFGF18 had signiﬁcantly
lower cartilage degeneration width (28 and 37% respectively)
and moreover animals given 10 µg rhFGF18 demonstrated a
27% increase of viable cartilage matrix. After 3 additional weeks
without treatment cartilage degeneration scores of the medial
tibia were signiﬁcantly decreased 38% after treatment with 10
µg rhFGF18 1x/week, which resulted in a signiﬁcant decrease
(31%) of cartilage degeneration in the overall joint. Dose respon-
sive beneﬁt was seen in the signiﬁcant cartilage degeneration
parameter and severe matrix loss, as measured by collagen
degeneration, was improved with the once per week dosing reg-
imen, therefore providing the best balance of beneﬁcial effects
versus lack of detrimental effects.
Conclusions: Overall, these results demonstrate that rhFGF18
can stimulate formation of new cartilage in an animal model
of OA, and suggest that rhFGF18 might have clinical utility for
treatment of this disease. rhFGF18 is currently tested in clinical
trials.
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Purpose: MMP-9, or called gelatinase B, is critical for the re-
cruitment of T cells, macrophages, and synovial ﬁbroblasts in
synovial membrame, which often initiates a cascade of degrada-
tive events through several pro-inﬂammatory cytokines including
interleukin 1 (IL-1) and tissue necrosis factor alpha (TNF-α).
MMP-9 is also important for the formation of growth plate car-
ilage and upregulated in OA and injured joint, but its roles in
cartilage degradation after injury is not clear. The aim of this
study was to establish a murine model to study overload injury
in cartilage without alternating joint kinematics and to test our
hypotheses that load-injury in cartilage alone induces cartilage
degradation in part by chronical joint inﬂammation and that the
